Header
For Healthcare Professionals

India: Other benefits vs. Glimepiride

3-2-1 banner

Other benefits vs. Glimepiride

Empagliflozin demonstrates lower risk of hypoglycaemia¹

16-9-copy-3@2x
16-9-copy-3@2x

FDC: Fixed-dose combination, HbAlc: Glycated haemoglobin, SE: Standard error, EMPA: Empagliflozin, LINA: Linagliptin, Cl: Confidence interval.

 

References:
  1. Salsali A, et al. Diabetes Obes Metab. 2018; 20(12):2768-2777.
  2. Gallwitz B, et al. Lancet. 2012;380:475-83.

Linagliptin demonstrates lower risk of hypoglycaemia1

16-9-copy-4@2x
16-9-copy-4@2x

FDC: Fixed-dose combination, HbAlc: Glycated haemoglobin, SE: Standard error, EMPA: Empagliflozin, 
LINA: Linagliptin, Cl: Confidence interval.

 

References:
  1. Salsali A, et al. Diabetes Obes Metab. 2018; 20(12):2768-2777.
  2. Gallwitz B, et al. Lancet. 2012;380:475-83.

Greater weight loss benefit of Empagliflozin vs. Glimepiride1*

16-9-copy-3@2x
16-9-copy-3@2x

*Glyxambi® is not indicated for weight reduction.
FDC: Fixed-dose combination, Cl: Confidence interval, SE: Standard error, BP: Blood pressure.

 

References:
  1. Salsali A, et al. Diabetes Obes Metab. 2018; 20(12):2768-2777.
  2. Gallwitz B, et al. Lancet. 2012;380:475-83.

Greater weight loss benefit of Linagliptin vs. Glimepiride1*

16-9-copy-4@2x
16-9-copy-4@2x

*Glyxambi® is not indicated for weight reduction.
FDC: Fixed-dose combination, Cl: Confidence interval, SE: Standard error, BP: Blood pressure.

 

References:
  1. Salsali A, et al. Diabetes Obes Metab. 2018; 20(12):2768-2777.
  2. Gallwitz B, et al. Lancet. 2012;380:475-83.

MLR ID: PC-IN-104937
Expiry Date: 7/9/2027